A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) (StrateGIST FrontLine)
Principal Investigator
Leonidas Mavroeidis
Contact us
Email: Latephasehaematology@ouh.nhs.uk
IRAS number
1013762